Author | Jonathan A. Ledermann, MD | OncLive

Author | Jonathan A. Ledermann, MD


Dr. Ledermann on Rationale for ARIEL3 Trial in Ovarian Cancer

October 09, 2019


Jonathan A. Ledermann, MD, discusses the rationale for the randomized, double-blind, placebo-controlled, phase III ARIEL3 trial which explored rucaparib as maintenance therapy in women with high-grade, recurrent ovarian cancer who previously received platinum-based chemotherapy.